ActiveMax® Human EPO (EPO-H4214) is expressed from human 293 cells (HEK293). It contains AA Ala 28 - Arg 193 (Accession # AAH93628.1).
Predicted N-terminus: Ala 28
This protein carries no "tag".
The protein has a calculated MW of 18.4 kDa. The protein migrates as 30-37 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>97% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ActiveMax® Human EPO on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 97%.
Immobilized Human EPO, Tag Free (Catalog # EPO-H4214) at 10μg/mL (100 μL/well) can bind Human EPO R, Fc Tag (Catalog # EPR-H5253) with a linear range of 0.013-0.12 μg/mL.
Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. EPO is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. is synthesized by renal peritubular cells in adults, with a small amount being produced in the liver. Regulation is believed to rely on a feed-back mechanism measuring blood oxygenation. Constitutively synthesized transcription factors for EPO, known as hypoxia-inducible factors (HIFs), are hydroxylated and proteosomally digested in the presence of oxygen. It binds to the erythropoietin receptor (EpoR) on the red cell surface and activates a JAK2 cascade. Erythropoietin has its primary effect on red blood cells by promoting red blood cell survival through protecting these cells from apoptosis. It also cooperates with various growth factors involved in the development of precursor red cells. EPO has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It has also been shown that erythropoietin can increase iron absorption by suppressing the hormone hepcidin. Erythropoietin has been shown to interact with the Erythropoietin receptor as its mechanism of action within the body. erythropoietin plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process.
- (1) Jacobson LO, et al., 1957, Nature 179 (4560): 633–4.
- (2) Fisher JW, et al., 1996, British journal of haematology 95 (1): 27–32.
- (3) Jelkmann W ., 2007, Eur. J. Haematol. 78 (3): 183–205.
- (4) Ashby DR, et al., 2010, Haematologica 95 (3): 505–8.
- (5) Middleton S A., 1999, J. Biol. Chem. (UNITED STATES) 274 (20): 14163–9.
- (6) Haroon ZA, et al., 2003, Am. J. Pathol. 163 (3): 993–1000.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.